An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Researchers and doctors noticed a big jump in new mothers using a class of drugs called GLP-1 receptor agonists between 2018 and 2025. That’s the main news: more postpartum people are being prescribed or are taking these medicines in the years after giving birth. The report flags a trend and raises questions about why this is happening and what it means for postpartum health. GLP-1 receptor agonists are medications that copy a natural gut hormone (called GLP-1) that helps control blood sugar and appetite. A few brand names you may have heard are Ozempic and Wegovy, though there are others. In simple terms, these drugs make you feel less hungry, slow how quickly your stomach empties, and help lower blood sugar. They were originally developed for diabetes and later approved for weight management in some cases. The underlying study or report is tracking prescription and usage data over several years and found a marked increase after 2018 through 2025. The snippet doesn’t say whether this comes from a single hospital, a national database, insurance claims, or surveys, nor does it give exact numbers or how many people were involved. So we should be cautious: the finding shows a trend but we don’t know from the snippet how large the increase was in percentage terms, or whether it was concentrated in particular regions, age groups, or medical situations. This trend matters because postpartum people face unique challenges: recovery from delivery, breastfeeding considerations, shifting metabolism, and occasional postpartum weight changes. If more new mothers are using GLP-1 drugs, it could change short-term and long-term health outcomes for them and their babies. Clinicians, new parents, and policymakers would care because this affects counseling around breastfeeding, managing postpartum weight or diabetes, and ensuring safe medication use after pregnancy. There are important caveats. The summary doesn’t tell us whether these women were advised by doctors to use the drugs, whether they were breastfeeding, or whether the drugs were used for diabetes, weight, or other reasons. Safety data on GLP-1 use during breastfeeding is limited, and these drugs can have side effects like nausea, vomiting, and, rarely, more serious issues. They are prescription medications and some indications require official approval; using them after pregnancy should involve a clinician’s guidance. Because the snippet is brief, it doesn’t establish cause — increased use might reflect wider availability, more marketing, changing guidelines, or underlying rises in conditions like diabetes or obesity. Bottom line: GLP-1 drug use among new mothers has risen notably between 2018 and 2025, but the short summary doesn’t give enough detail to judge safety or reasons; anyone postpartum considering these medications should talk with their healthcare provider about risks, benefits, and breastfeeding implications.
Source: Infectious Disease Advisor